Tempus AI shares are higher in Monday trading (April 20, 2026), with the move tied to investor focus on Tempus’ recently announced launch of a novel pan-cancer HRD‑RNA algorithm. The company positioned HRD‑RNA as an AI-driven model designed to identify patients likely to respond to platinum-based chemotherapy or PARP inhibitors—an added layer of clinical decision support built on RNA data rather than traditional DNA-only approaches. (investors.tempus.com)

HRD status has become a key biomarker in oncology because it can help pinpoint patients who may benefit from specific therapies; Tempus’ pitch is that an RNA-based model can broaden usability when DNA signals are limited and improve scalability across tumor types. The launch also reinforces Tempus’ strategy of pairing diagnostic testing with software/algorithms that can deepen product differentiation and potentially expand monetization beyond a single lab test. (investors.tempus.com)

A central near-term question is timeline: the HRD‑RNA model is being rolled out with an initial research-use focus, with broader clinical availability expected later in 2026. Investors will also watch for evidence of commercial traction—provider adoption, test ordering trends, and whether algorithmic products lift average revenue per patient or strengthen biopharma demand for Tempus’ data-and-services offerings. (tipranks.com)